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Abstract: Thyroid cancer harbours in about 5% of thyroid nodules. The majority of them are well-differentiated cancers 
originating from the follicular epithelium, and are subdivided into papillary and follicular carcinomas. Undifferentiated 
carcinomas and medullary thyroid carcinomas arising from C cells are less common.
Although most thyroid nodules are benign, distinguishing thyroid cancer from benign lesions is crucial for an appropriate 
treatment and follow-up. The ﬁ  ne needle aspiration cytology (FNAC) allows the diagnosis of nature of thyroid nodules in 
the majority of cases. However, FNAC has some limitations, particularly in the presence of follicular lesions which can 
appear dubious in rare instances even at histology.
In an effort to improve diagnostic accuracy and offer new prognostic criteria, several immunohistochemical and molecular 
markers have been proposed. However, most of them have to be validated on large series before being used in routine 
practice.
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Introduction
Thyroid tumours: a worldwide health problem
The expression “thyroid tumour” identiﬁ  es a large variety of thyroid lesions which include well-
differentiated and benign neoplasm or goitre nodules as well as either differentiated cancers of follicular 
origin or poorly differentiated and de-differentiated cancers, along with medullary and anaplastic 
carcinomas, all arising as a thyroid nodule (Sakamoto et al. 1983; Rosai et al. 1992; Baloch and 
LiVolsi, 2003).
Thyroid carcinomas account for about 90% of malignancies of the entire endocrine system and for 
1% of human malignancies (Landis et al. 1998; Wong and Wheeler, 2000; Jemal et al. 2007). Annual 
incidence rate throughout the world, widely ranges from 0.5 to 13.6 cases per 100,000 inhabitant per 
year (Arnbjörnsson et al. 1986; Kolonel et al. 1990; Akslen et al. 1993; Colonna et al. 2002; Hernandez, 
2003; Gomez Segovia et al. 2004).
Epidemiological reports of thyroid cancer are in striking contrast with statistical data on the 
epidemiology of cancerous diseases. In fact, data from the US through the Surveillance, Epidemiology, 
and End Results (SEER) program, and the European data from the GLOBOCAN 2002 project of the 
International Agency for Research on Cancer, indicate a progressive stabilization of the incidence and 
a decline of the mortality rates for most cancers from the year 2000 (Parkin et al. 1999; Greenlee et al. 
2000; Hayat et al. 2007; Jemal et al. 2007). On the contrary, in worldwide population the thyroid 
cancer incidence has increased (Parkin et al. 2002; Hodgson et al. 2004; Davies and Welch, 2006; 
Albores-Saavedra et al. 2007; Jemal et al. 2007) and some studies have also reported increased mortality 
either in Europe or in USA (Howe et al. 2001; Parkin et al. 2002). However, the prognosis for thyroid 
cancer is good, so it accounts for rather few deaths (35,000 or 0.5% of all cancer deaths) with a 5 years 
survival rate of more than 90% (Mazzaferri and Kloos, 2001). Apart from patient age and histological 
type, prognosis is strongly determined by the stage of tumour at diagnosis and initial treatment. 
Therefore, a correct and early diagnosis is crucial for the outcome of the disease. In an effort to improve 238
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diagnostic and prognostic accuracy, speciﬁ  c and 
reproducible biomarkers of thyroid malignancy 
are necessary.
Aim of this review is an overview of well-established 
tests with a special emphasis for the effective role 
pertaining to new potential thyroid biomarkers in 
relying on the last knowledge of the molecular 
genetic events promoting thyroid tumorigenesis.
Diagnosis of Thyroid Tumour 
and Identiﬁ  cation of Malignancy
The identiﬁ  cation of malignancy in a thyroid nod-
ule is based on different clinical, biochemical, 
imaging and pathological tools.
Thyroid tumours arise almost invariably as a 
nodule, but the largest majority (about 95%) of 
thyroid nodules are benign (Utiger, 2005). Malig-
nant thyroid nodules include papillary and fol-
licular carcinomas, both originating from 
follicular epithelium, and a small number of undif-
ferentiated cancer. Medullary thyroid carcinomas 
account for less than 5% of thyroid nodules and 
exhibit a speciﬁ  c circulating biomarker, i.e. calci-
tonin (CT), the levels of which clearly indicate its 
biological nature.
Biological malignancy of thyroid 
tumours arising from follicular cells
The majority of follicular tumours (more than 90%) 
are well-differentiated, usually retain in varying 
degrees biological properties of normal follicular 
cells (i.e. iodine uptake; thyroglobulin synthesis), 
and are mainly divided into papillary (PTC) and 
follicular (FTC) carcinomas on the basis of 
the histological features (Rosai et al. 1992; 
Schlumberger, 2007).
PTC is the most common type of thyroid cancer 
(about 85%), with the highest rate of incidence in 
women (F: M ratio 4–8:1) and its incidence has 
increased in the last 20 years in different parts of 
the world (Haselkorn et al. 2000; Hodgson et al. 
2004; Lang et al. 2007). The major risk factor for 
the development of PTC is a history of radiation 
exposure, especially during childhood, as proved 
by the consequences of the Chernobyl accident 
(Ron et al. 1995; Cardis et al. 2005; Schlumberger 
et al. 1999; Williams, 2000; Tronko et al. 2006). 
Several further risk factors including family history 
of thyroid cancer or benign thyroid disease, famil-
ial adenomatous polyposis of the colon and 
reproductive life in females may play a role 
(Navarro Silvera et al. 2005; Schlumberger, 2007). 
The possible influence of nutritional factors, 
including iodine nutrition and the exposition to 
chemical and physical contaminants of volcanic 
origin are presently under investigation in Sicily. 
(Frasca et al. 2008). PTC may arise as a single 
thyroid nodule; however, in at least 20% of cases, 
the evidence of a single nodule of PTC corresponds 
to a multifocal spread by a microscopic examina-
tion (Sherman, 2003). The biological malignancy 
of PTC is associated with a speciﬁ  c follicular cell-
type, showing typical nuclear features, such as 
nuclear grooves and “ground glass” appearances 
(Rosai et al. 1992; Hermanek et al. 2002). PTC 
variants are classiﬁ  ed on the basis of architectural 
and cytoplasmic features which may be associated 
with biological malignancy (Rosai et al. 1992; 
Hermanek et al. 2002; Trovato, 2007, p 191–202). 
Speciﬁ  cally, PTC variants include the classic, fol-
licular, oncocytic, tall cells and diffuse sclerosing 
forms. Finally, PTC may be classiﬁ  ed as microcar-
cinomas when measuring 10 mm or less in diam-
eter. The outcome of PTC is variable depending 
mainly from patient’s age, size of tumour, patho-
logical classiﬁ  cation and presence of distant metas-
tases (Mazzaferri, 2000; Pellegriti et al. 2004; 
Frasca et al. 2008). Lymph-node involvement is 
frequent and early in PTC, with speciﬁ  c localiza-
tion to lymph nodes next to the trachea or windpipe, 
called the para-tracheal lymph nodes (Hermanek 
et al. 2002). Vascular invasion is rare, and distant 
metastases are observed in less than 10% of cases 
(LiVolsi, 1990; Grebe and Hay, 1997; Al-Brahim 
and Asa, 2006). Generally, the prognosis of PTC 
is excellent.
FTC is less frequent than PTC (5% to 15% of 
thyroid malignancies), and occurs mostly in 
women with a F:M ratio 2:1(Schlumberger, 2007). 
FTC usually presents as a solitary nodule irregu-
larly bordered with invasive aspects in adjacent 
thyroid tissue. Its biological malignancy is linked 
to the pattern of tumour growth as well as to the 
morphology of tumour cells, and is based on the 
demonstration of vascular and capsular invasion. 
Through the cellular growth, the FTC architec-
tural structure varies from well-formed follicles 
to a solid growth pattern, and different patterns 
may coexist. Considering the cellular morphol-
ogy, FTC includes a variant with dark nucleus 
and eosinophilic cytoplasm and a less frequent 
variant with dark nucleus and oncocytic cytoplasm 239
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which has a higher grade of malignancy (Trovato 
et al. 2004). Through the degree of the invasion, 
the FTC is distinguished in minimally and widely 
invasive types, with a more favourable prognosis 
for the minimally invasive form. Apart from the 
histological type, the behaviour of FTC depends 
on patient’s age, size of tumour, extra-thyroidal 
extension and distant metastases (Hermanek et al. 
2002; Schlumberger, 2007). FTC shows a major 
degree of aggressiveness with respect to PTC. In 
fact, FTC has a greater rate of recurrence and is 
more frequently associated with extra-glandular 
extension and distant metastases, preferring to 
spread through the blood stream (Rosai et al. 
1992; LiVolsi, 1990; Grebe and Hay, 1997). FTC 
outcome is generally less favourable than PTC 
prognosis.
The undifferentiated carcinomas neither exhibit 
follicular or papillary patterns, nor retain the nor-
mal follicular functions, and are referred to as 
anaplastic carcinomas (ATC) (Grebe and Hay, 
1997). ATC represents 1% of thyroid cancers and 
is one of the most aggressive human malignancies 
with a near 100% mortality. Characteristically, 
ATC grows and metastasizes quickly and does not 
respond to radioiodine therapy. Although histo-
logical features distinguish the ATC in two vari-
ants (spindle cells and giant cells), the biological 
malignancy is similar for both variants and the 
prognosis is bad because of the rapid aggressive 
course of the disease (Rosai et al. 1992; Pellegriti 
et al. 2002).
Biological malignancy of thyroid tumours 
arising from parafollicular C-cells
Medullary thyroid carcinomas (MTC) derive from 
the parafollicular C cells of the thyroid that produce 
CT. It is less common (5% of thyroid cancers) than 
epitheliomas, and its management differs from that 
of follicular cell-type-speciﬁ  c cancers in many 
aspects (Wells and Franz, 2000). MTC may occur 
either in sporadic (75%) or familial form (25%) 
(LiVolsi, 1990). Commonly, the sporadic MTC 
type appears as a solitary nodule located in the 
middle third of the thyroid lobe, where C-cell 
concentration is intense. Instead, the heritable 
MTC type is multifocal, bilateral and associated 
to C cells hyperplasia. MTC exhibit a speciﬁ  c 
circulating biomarker, i.e. CT, produced by the 
tumour cells. In fact, basal CT levels are elevated 
virtually in all patients with the disease, and the 
highest values are observed in patients with the 
greatest tumour mass. The routine measurement 
of serum CT has been proposed in the diagnostic 
work-up of all patients with thyroid nodules in 
order to allow the pre-operative diagnosis of MTC 
even in a sub-clinical phase (Pacini et al. 1994; 
Vierhapper et al. 1997; Elisei et al. 2004). Clinical 
trials have demonstrated that MTC diagnosed 
through CT screening had a signiﬁ  cant lower stage 
at diagnosis and a better prognosis after a 10-year 
period of follow-up. The measurement of plasma 
CT levels, both basal and after a provocative test 
(i.e. pentagastrine test), allows the identiﬁ  cation 
of MTC at a pre-clinic stage and in the family 
members of patients with inherited MTC. Further-
more, RET germinal mutations are employed to 
identify inherited MTC, both isolated and occur-
ring in MEN (Elisei et al. 2007).
The aggressiveness of MTC depends on the 
proliferation and growth rate of the tumor. Although 
there are several histological variants of MTC, 
most of them have no importance in determining 
the biological aggressiveness of MTC.
MTC metastasizes to regional lymph nodes, but 
may invade blood vessels and distant metastases 
are present at diagnosis in up to 20% of cases 
(Rosai et al. 1992; Wells and Franz, 2000). Clinical 
prognostic factors in MTC include age at diagno-
sis, male gender, tumour size and initial extend of 
the disease (Pellegriti et al. 2003).
Diagnostic Approaches to Thyroid 
Cancer: Which Biomarkers May be 
Useful to Recognize the Malignancy
Diagnostic markers are constantly investigated to 
overcome the difﬁ  culties to distinguish benign 
from malignant thyroid lesions.
In an effort to improve diagnostic accuracy, 
many immunohistochemical and molecular 
biomarkers have been proposed, but the clinical 
implications have been demonstrated only for some 
of them. Beyond their diagnostic value, these 
biomarkers should be able to offer prognostic cri-
teria, and may also play a role in detecting persist-
ent or recurrent disease as well as in choosing the 
therapeutic strategies. Particularly, they may 
improve the sensitivity and accuracy of FNAC, 
and so may contribute to reduce the frequency of 
surgical procedures by identifying those patients 
with benign lesions who do not require surgical 
excision.240
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Based on the methodology applied to recognize 
the diagnostic traits, it is possible to distinguish 
cytological and histological thyroid biomarkers, 
such as immunohistochemical and molecular 
biomarkers.
Cytological evaluation
Fine needle aspiration cytology (FNAC), routinely 
performed in the clinical practice, allows the diag-
nosis of the nature of thyroid nodules with an 
accuracy of over 90% (Hamburger, 1994; Gharib, 
1996; Gharib and Papini, 2007).
In fact, FNAC is the most effective test 
adopted for an accurate diagnosis of PTC, ATC and 
MTC nodules in the pre-surgical stage. The PTC 
identiﬁ  cation by FNAC is assessed primarily on 
the basis of nuclear changes (Baloch and LiVolsi, 
2005; Das et al. 2004; Das, 2005; Trovato, 2007, 
p 191–202). PTC nuclei are large, elongated, 
overlapping and crowding with irregular outlines, 
intranuclear and cytoplasmic pseudo-inclusions, 
ground-glass appearance, multiple small nucleoli 
and deep grooves (Fig. 1A). Instead, the observation 
of spindle or giant cells in cytological smears of 
FNAC allows to identify ATC, while the detection 
of monomorphic, large polygonal cells related to 
the diffused neuroendocrine cell system leads to a 
diagnosis of MTC (Trovato, 2007, p 191–202).
However, FNAC has some limitations 
(Hamburger, 1994; Gharib, 1996; Gharib and 
Papini, 2007). FNAC is less useful to diagnose 
FTC, because the major criteria for differential 
diagnosis are the capsular and vascular invasion 
which cannot be seen on cytological smears. There-
fore, the FTC diagnosis is assessed only after 
surgery through the histological evaluation (Baloch 
et al. 2002; Louvel and Vielh, 1999; Deveci et al. 
2006; Haugen et al. 2002). When a follicular or 
Hürthle cell proliferation is displayed, cytology 
cannot differentiate the carcinoma from its benign 
counterpart, and the histological veriﬁ  cation of the 
lesion is indicated. Further, FNAC interpretation 
is difﬁ  cult when papillary or medullary cancer, that 
usually are easy to diagnose for an expert cytolo-
gist, do not exhibit the typical features but the 
cellular pattern is atypical; in such cases the lesion 
may be misinterpreted.
Obviously, FNAC has a diagnostic value when 
the cellularity is adequate. Inadequate FNAC 
(15%–20%, in different series) should be repeated, 
and surgical treatment may be recommended.
Histological examination
Histological evaluation improves the sensitivity 
and accuracy of FNA overcoming the difﬁ  culties 
to distinguish benign from malignant thyroid 
lesions.
Specially, histological examination is required 
to achieve the diagnosis of FTC, which is com-
posed by follicular cells with dark nuclei and 
cytoplasms being eosinophilic in most of FTC and 
oncocytic in the Hürthle cells variant. In fact, in 
both cases the diagnosis of malignancy is based on 
the demonstration of vascular and capsular inva-
sions, which are absent in follicular and oncocytic 
adenomas (Louvel and Vielh, 1999; Haugen et al. 
2002) (Fig. 1B). Furthermore, histological 
examination allows to distinguish the minimally 
invasive (encapsulated) and widely invasive cancer 
types thought the pattern of growth of cancerous 
follicular cells.
However, the diagnosis of FTC may be difﬁ  cult 
even at the ﬁ  nal histological examination, when 
the capsular and vascular invasion is minimal.
Immunohistochemical biomarkers
The need to add immunohistochemical biomarkers 
to the cytological and histological investigations 
above illustrated derives from the difﬁ  culties of a 
differential diagnosis in borderline cases (e.g. 
carcinomas with atypical cellular pattern, follicular 
or oncocytic lesions, such as follicular adenomas 
and carcinomas; Hürthle cells adenomas and car-
cinomas; follicular variant of PTC). Immunohis-
tochemistry is an important technique able to 
Figure 1.  A. Cytological smears of papillary thyroid carcinoma. MGG 
stain, obj ×40. B. Histological features of follicular thyroid carcinoma. 
E-E stain, obj ×10. C. c-met immunoreaction in papillary thyroid 
carcinoma, obj ×20. D. MDR2 expression in medullary thyroid 
carcinoma, obj ×20.241
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recognize specific proteins on cytological or 
histological specimens. All thyroid diagnostic 
immunomarkers share the ability to be expressed 
when the carcinoma appears. However, the 
expression of the currently known biomarkers is 
strongly variable in sensitivity and speciﬁ  city and 
then, to date, none of them have been routinely 
adopted in cytological and/or histological diagnostic 
procedures.
Mainly, the immunohistochemical biomarkers 
are employed to reach an accurate diagnosis of 
PTC and MTC, whereas there are no valued 
biomarkers to facilitate the diagnosis of FTC.
Immunohistochemical investigation of PTC had 
identiﬁ  ed several biomarkers, showing varying 
degrees of sensitivity and speciﬁ  city. The biomar-
kers that up to date appear to yield the higher 
sensitivity and speciﬁ  city include Hector Battifora 
mesothelial cell 1 (HBME-1), high molecular 
weight cytokeratin 19 (CK19), galectin-3, c-met.
HBME-1 is a monoclonal antibody generated 
against the microvillous surface of mesothelial 
cells of mesothelioma. It has been reported to be 
reactive in most cases of papillary thyroid carci-
noma, and absent in benign thyroid lesions (Sack 
et al. 1997; de Matos et al. 2005). So, HBME-1 is 
quite specific marker for PTC. However, this 
biomarker shows a poor sensitivity, because PTC 
lesions with oncocytic cells are uncreative (Sack 
et al. 1997), and a negative result for HBME-1 does 
not preclude the diagnosis of carcinoma.
CK19 is a high-molecular-weight cytokeratin 
showing a strong sensitivity but poor speciﬁ  city 
for PTC. In fact, the immunoexpression of CK19 
is assessed to support the PTC diagnosis in bor-
derline lesions because of its widespread reactivity 
(Ramphael et al. 1995; Rorive et al. 2002), but 
positive immunoreactivity for CK19 of varying 
degrees has been observed in normal thyroid tissue 
around PTC and in benign thyroid lesions, thus 
limiting the usefulness of this marker (Cheung 
et al. 2001).
Galectin-3, a member of the beta-galactoside 
binding family of lectins, is strongly expressed in 
PTC, mostly in the classic variant. Immunoreactiv-
ity for galectin-3 was also reported in a number of 
FTC, and it has been considered of some value in 
differentiating between benign and malignant fol-
licular lesions (Gasbarri et al. 1999; Saggiorato 
et al. 2004; Nucera et al. 2005). Therefore, immu-
nocytochemistry with anti-Galectin-3 antibodies 
has been proposed as an auxiliary procedure to 
conventional cytology in the diagnostic work-up 
of thyroid nodules (Bartolazzi et al. 2001; 
Saggiorato et al. 2004; Collet et al. 2005). How-
ever, the speciﬁ  city of Galectin-3 is poor because 
of its reactivity in benign goitre and thyroditis 
lesions (Orlandi et al. 1998; Mehrotra et al. 2004). 
In addition, other studies have found that galectin-3 
is not a sensitive indicator of thyroid cancer because 
of the possibility of false-negative results in speciﬁ  c 
cases, such as Hürthle cell proliferation or mini-
mally invasive follicular carcinomas (Oestreicher-
Kedem et al. 2004; Mehrotra et al. 2004).
Based on the literature, none of the above dis-
cussed biomarkers appears to be reliable in iden-
tifying all malignant thyroid lesions in highly 
speciﬁ  c and sensitive manner. As compared with 
the use of single biomarker, the combination of 
two or three markers may represents a more accu-
rate immunohistochemical approach in the dif-
ferentiation of malignant tumors from their benign 
counterparts, especially in controversial categories 
(Asa, 2005; de Matos et al. 2005; Prasad et al. 
2005; Saggiorato et al. 2005; Nasr et al. 2006).
The c-Met proto-oncogene, localized on the 
long arm of chromosome 7, encodes for a tyrosine-
kinase receptor, namely, c-met. Its high afﬁ  nity 
ligand is a pleiotropic mesenchyme-derived 
cytokine, the hepatocyte growth factor (HGF). 
HGF/c-met interaction can promote different 
responses (i.e. scattering, growth and morphogen-
esis) in epithelial cells through activation of several 
pathways. Among thyroid cancers, PTC is associ-
ated with marked over-expression (up to 100 folds) 
of the c-met proto-oncogene, which, instead, is 
rarely expressed in other thyroid tumors, including 
FTC, ATC and MTC (Di Renzo et al. 1995; Oyama 
et al. 1998; Trovato et al. 1998). Over-expression 
of c-met has been found in 75%–100% of PTC, 
regardless of the histological variants; it was not 
associated with gene ampliﬁ  cation or rearrange-
ments, and the protein produced by the tumor cells 
did not show structural alterations. Our group have 
demonstrated for the ﬁ  rst time the immunohisto-
chemical co-expression of HGF and c-met in PTC 
cells (up to 80% of PTC studied), raising the pos-
sibility of met activation through an autocrine loop 
(Trovato et al. 1998). Moreover, we have correlated 
the expression of HGF/c-met with that of STAT3, 
one member of the Signal Transducers and Activa-
tors of Transcription, which is known to mediate 
the morphogenetic effects of HGF/c-met (Boccaccio 
et al. 1998). We have demonstrated that the whole 242
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morphogenetic pathway HGF/c-met/ STAT3 is 
over-expressed in PTC (Fig. 1C), and is highly 
speciﬁ  c for this type of thyroid malignancy (100% 
of PTC tested; none of the FTC or ATC), suggest-
ing that such autocrine signalling pathway may be 
relevant for the establishment of the papillary 
phenotype (Trovato et al. 2003). Met and/or HGF 
and/or STAT3 are not expressed in normal thyroid 
tissue, but in our hands, a number of totally benign 
lesions were HGF
+/c-met
+ without being STAT3
+ 
(Trovato et al. 1998; Trovato et al. 2003). Only a 
subset of follicular adenomas expressed the whole 
c-met/HGF/STAT3 pathway, and we have hypoth-
esized that these adenomas may progress to PTC 
(Trovato et al. 2003). Since the expression of HGF, 
c-met and STAT3 appears to be a typical trait of 
almost every case of PTC, including all the histo-
logical variants, these molecules may be included 
among the best candidates to the role of PTC mark-
ers. Clinical trials on larger series are required to 
verify their usefulness either in the diagnosis of 
PTC or in the recognition of PTC precursor lesions 
(Trovato et al. 1998; Trovato et al. 2003).
CT is produced from C cells and therefore 
positive immunoreaction of malignant cells with 
anti-CT antibodies allows an unequivocal diagno-
sis of MTC. Despite the CT expression being 
highly speciﬁ  c, its immunoreaction is not con-
stantly detected in MTC. Chromogranin is a more 
sensitive immunomarker with respect to CT and 
its use is foreseen in each diagnostic algorithm for 
MTC (Rosai et al. 1992; Wells and Franz, 2000).
Molecular biomarkers
The thyroid molecular biomarkers correspond to 
genetic mutations arising in malignant thyroid cells 
and recognizable by the molecular biology tech-
niques. Several molecular alterations (mutations 
and/or gene rearrangements) have been described 
in thyroid malignancies, and it has been demon-
strated that different genes and signalling pathways 
are involved in the development of PTC and FTC 
as well as MTC. The expression of each molecular 
marker may be studied on frozen specimens of the 
neoplastic tissue by using PCR techniques.
The more common genetic abnormalities found 
in PTC are the radio-induced RET/PTC rearrange-
ments and the mutations of BRAF and RAS genes, 
while PAX8/PPARγ fusion gene and the loss of het-
erozigosity (LOH) on 3p and 7q loci as well as RAS 
mutations are frequently encountered in FTC.
BRAF is a serine—threonine kinase involved 
in the mitogen-activated protein kinase (MAPK) 
pathway. Mutations of the BRAF gene, located on 
the long arm of chromosome 7, represent the most 
common genetic alteration in PTC and seem very 
close to this type of cancer, because they are not 
found in other histotypes (Nikiforova et al. 2003; 
Trovisco et al. 2005). BRAF point mutations at 
600 ( BRAF
V600E) and—less frequently—at 599 
and 601 locations, resulting in constitutive kinase 
activation, have been detected in about 26%–69% 
of sporadic PTCs of adults (Soares et al. 2003; 
Trovisco et al. 2004; Cohen et al. 2003; Trovisco 
et al. 2005; Moretti et al. 2006). Recently, a BRAF 
rearrangement by paracentric inversion of chromo-
some 7q followed by the fusion between AKAP9 
and BRAF genes has been recognised in a subset 
of radiation-induced PTC (Ciampi et al. 2005). 
BRAF mutations are strongly associated with the 
classic variant of PTC, displaying the typical 
nuclear features and the papillary architecture, 
although they have been also reported in tall cell 
or columnar cell variants (Nikiforova et al. 2003; 
Begum et al. 2004; Trovisco et al. 2004). In several 
studies, the presence of BRAF mutations has been 
associated with older age of patients, more 
advanced stage of the disease at presentation and 
higher frequency of recurrence and/or metastases 
(Namba et al. 2003; Nikiforova et al. 2003; Vasko 
et al. 2005; Riesco-Eizaguirre et al. 2006). More-
over, a signiﬁ  cant incidence of BRAF
V600E muta-
tion has been found in undifferentiated thyroid 
cancers, suggesting that ATC may arise from more 
typical forms of PTC and that BRAF signalling 
may be functionally relevant in tumor progression 
(Nikiforova et al. 2003; Begum et al. 2004; Soares 
et al. 2004; Trovisco et al. 2004; Santarpia et al. 
2008). However, the relationship between BRAF 
mutations and more aggressive tumour behaviour 
have not been conﬁ  rmed in a number of other stud-
ies (Trovisco et al. 2005; Fugazzola et al. 2006), 
and a high frequency of BRAF mutations has been 
reported in microcarcinomas with an excellent 
prognosis (Kim et al. 2005; Fugazzola et al. 2006; 
Rodolico et al. 2007). In a very recent study in 
Sicily (Frasca et al. 2008) BRAF
V600E mutation 
was found in 52% classical PTC and in 26% in the 
tall cell variant. The mutation was found in macro-
carcinomas more frequently than in microcarcino-
mas, is associated with extra-thyroid invasion and 
is positively correlated with Matrix Metalloprotei-
nases 9 expression. BRAF mutation was found 243
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more prevalent in the Eastern part of the Island 
thus suggesting a possible environmental inﬂ  uence 
correlated to the volcanic nature of the large area 
surrounding Mount Etna. These data, taken 
together, underline how the BRAF mutations 
accompany the development of PTC, showing its 
relevant signiﬁ  cance in the PTC tumorigenesis. 
Thus, search for BRAF mutations might be used 
in clinical practice to reach the cytological diag-
nosis of PTC and to select patients for a more 
aggressive initial treatment (Xing et al. 2004; 
Domingues et al. 2005; Pizzolanti et al. 2007; 
Sapio et al. 2007). Methods for rapid detection of 
these mutations on FNAC samples have been 
already developed (Xing et al. 2004).
The second most common genetic alteration 
described in PTC is the RET/PTC rearrangement. 
RET is a proto-oncogene, located on chromosome 
10q11.2, encoding for a transmembrane tyrosine-
kinase receptor (Santoro et al. 2004). The rear-
rangements known as RET/PTC lead to the 
constitutive activation of the tyrosine kinase recep-
tor RET, that activate the RAS–RAF–MEK and 
other signalling cascades, thus promoting cell 
growth and transformation (Grieco et al. 1990). 
The most common RET/PTC rearrangements, 
namely RET/PTC1 and RET/PTC3, result in an 
intrachromosomal inversion of the long arm of 
chromosome 10 leading to the fusion of RET with 
the H4/D10S170 or RFG/ELE1 genes, respectively 
(Grieco et al. 1990; Santoro et al. 1994). Such gene 
rearrangements are more prevalent in pediatric 
patients and in PTCs developed following radiation 
exposure (Nikiforov et al. 1997; Nikiforov et al. 
1999). In fact, in the adult population, the incidence 
rate of RET rearrangements is about 15%–20% of 
PTC, while in post-Chernobyl PTCs they have 
been found in up to 87% of cases. RET/PTC rear-
rangements are restricted to PTC, including both 
conventional PTC and oncocytic and diffuse scle-
rosing variants, thus representing a marker for this 
type of thyroid tumour. For this reason, RET/PTC 
detection in FNAC specimens have been proposed 
as a diagnostic adjunctive tool in the cytological 
evaluation of thyroid nodules (Salvatore et al. 
2004; Domingues et al. 2005; Pizzolanti et al. 
2007; Sapio et al. 2007). However, its speciﬁ  city 
has been questioned because of the identiﬁ  cation 
of RET/PTC in non-neoplastic follicular cells in 
Hashimoto’s thyroiditis (HT), oncocytic tumors, 
and other benign lesions, and this expression 
variability should be taken into account for the 
molecular diagnosis of thyroid lesions (Cinti et al. 
2000; Elisei et al. 200; Nikiforova et al. 2002; 
Rhoden et al. 2004). Moreover, these rearrange-
ments reveal the appearance of PTC cells in thyroid 
gland and seem deserved of prognostic signiﬁ  -
cance. Despite this, the vast majority of the RET/
PTC positive tumors are stage I at presentation. 
(Nikiforov et al. 1999; Viglietto et al. 1995). 
Finally, RET/PTC rearrangements are a common 
ﬁ  nding in papillary microcarcinomas, thus sug-
gesting that they represent an early event in the 
tumorigenesis.
Another type of genetic alteration found in PTC 
is RAS point mutations involving speciﬁ  c regions 
(codons 12, 13 and 61) of the three RAS oncogenes 
namely, H-RAS, K-RAS, and N-RAS. RAS muta-
tions are found not only in PTC, but also in FTC 
and ATC, and this genetic abnormality seems closer 
to the follicular cancers rather than to classic PTC. 
The incidence of RAS mutations is variable in 
these different histotypes, ranging from 0%–50% 
in PTC, 14%–62% in FTC, and 0%–60% in ATC. 
Among PTC, the follicular variant shows the high-
est prevalence of RAS mutations, as well as a lower 
prevalence of BRAF mutations and RET/PTC 
rearrangements, in respect to the conventional PTC 
and the other variants (De Micco, 2003; Zhu et al. 
2003; Giordano et al. 2005). Moreover, RAS muta-
tions are encountered even in benign follicular 
adenomas with a frequency ranging from 0%–85%. 
Nevertheless, a higher rate of RAS mutations in 
malignant rather than in benign thyroid tumours 
has been observed. These evidences suggest that 
RAS mutations represent the earliest events in 
cancer progression along the malignant pathway 
leading to FTC and ATC (Namba et al. 1990). It 
has been proposed that activating mutations in RAS 
oncogenes could be related to chromosomal and 
genomic instability, thus predisposing follicular 
cells to the accumulation of additional molecular 
abnormalities. However, the mutations of RAS 
have no diagnostic signiﬁ  cance to distinguish the 
follicular adenoma from FTC (Vasko et al. 2003; 
Zhu et al. 2003).
PAX8/PPARγ fusion gene and the loss of het-
erozigosity (LOH) on 3p and 7q loci may represent 
potentially useful molecular biomarkers of FTC. 
The paired box 8 (PAX8) gene, located on 2q13 
chromosome, and peroxisome proliferator-
activated receptor γ (PPARγ) gene, located on 3p25 
chromosome, encode thyroid-speciﬁ  c transcription 
factors. Pax-8 is a member of the Pax family of 244
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transcription factors, and is essential in the 
development of thyroid follicular cells and regula-
tion of thyroid-speciﬁ  c gene expression. Mutations 
of PAX8 have been identiﬁ  ed in cases of con-
genital hypothyroidism caused by thyroid dysgen-
esis (Macchia et al. 1998). PPARγ is a member of 
the nuclear hormone receptor superfamily that 
includes thyroid hormone, retinoic acid and andro-
gen and estrogen receptors. The two genes are 
involved in a chromosomal traslocation leading to 
the fusion of the exons 7, 8 and 9 of PAX8 with 
exon 1 of PPARγ. The PAX8/PPARγ fusion protein 
includes the DNA binding domains of PAX8 and 
the PPARγ nuclear receptor domains. PAX8-PPAR-
gamma disrupts normal transcriptional function of 
both transcriptional factors in thyroid follicular 
cells by inhibiting PPARγ trascriptional activation 
and dysregulating the PAX8 pathways (Kroll et al. 
2000; Gregory Powell et a Gregory Powelll, 2004; 
Ay et al. 2006). This type of mutation is frequently 
observed in FTC and seems to be involved in FA 
to FTC progression. In fact, only 10% of FA 
expresses PAX8/PPARγ fusion gene such as the 
ATC expresses infrequently this rearrangement 
(Nikiforova et al. 2002; Cheung et al. 2003; 
Nikiforova et al. 2003; Lacroix et al. 2004). In line 
with these results, the expression of PAX8/PPARγ 
may be supposed as a marker of the well-
differentiated FTC and its absence as a marker of 
tumour progress to rapidly fatal forms of thyroid 
carcinomas. Although the diagnosis of FTC is often 
problematic, the practical diagnostic use of this 
biomarker is limited because few clinical trials 
have been carried out to conﬁ  rm the effectiveness 
of this biomarker (Puxeddu and Fagin, 2001; 
Nakabashi et al. 2004).
LOH on chromosomes 3p and 7q is frequently 
observed in the early steps of follicular tumoral 
transformation (Grebe et al. 1997; Ward et al. 
1998; Zhang et al. 1998; Trovato et al. 1999; 
Trovato et al. 2004). The progression of the FA 
towards FTC is underlined through the appearance 
of both 3p and 7q LOH. LOH of chromosome 3 
is more signiﬁ  cantly found in FTC and follicular 
adenomas involving speciﬁ  c minimal common 
deleted regions corresponding to 3p25.3 and 
3p21.2 loci, respectively (Trovato et al. 1999). The 
highest rate of LOH on chromosome 7 is located 
on 7q21.2 locus. Characteristically, LOH on 
7q21.2 is speciﬁ  c for cell type because it involves 
only the benign and malignant thyroid lesions 
made up of dark nucleus and eosinophilic 
cytoplasm cells. Furthermore, to show speciﬁ  city 
for the cellular phenotype, the 7q21.2 LOH 
increases along with neoplastic transformation 
reaching a 100% of expression in FTC correlating 
with thyroid gland volume and the presence of 
multiple lesions ( Trovato et al. 2004). Thus, the 
7q21.1 LOH has been proposed as a diagnostic 
key to assist pathologists in the task of distinguish-
ing FTC from benign thyroid lesions. In fact, all 
suspected FTC lesions showing a prevalence of 
dark nucleus and eosinophilic cytoplasm cells may 
be included among benign lesions if they do not 
express LOH on 7q21.2 (Trovato et al. 1999; 
Trovato et al. 2004).
In MTC, the malignant transformation of C cells 
is characterized by the appearance of speciﬁ  c defects 
of the RET gene. RET germ-line mutations are 
inheritable occurring in hereditary MTC, whereas 
RET somatic mutations arise only in the context of 
the neoplastic C cells of the sporadic MTC. These 
differences have a practical application because the 
recognition of each RET germ-line mutation leads 
to an unequivocal diagnosis of hereditary MTC. 
Furthermore, RET germinal mutations are employed 
to identify inherited MTC, both isolated and 
occurring in MEN (Komminoth et al. 1995; Fink 
et al. 1996). Speciﬁ  cally, the germinal mutations 
involving the exons 10 and 11 are associated with 
MTC appearing in MEN 2A, while the germinal 
mutation of the exons 16 is linked to MTC arising 
in MEN 2B. To screen the isolated familial form of 
MTC, several germinal mutations located in exons 
10,11,13,14 and 15, respectively, are individualized 
(Marsh et al. 1997; Chiefari et al. 1998; Kebebew 
et al. 2000; Iacobone et al. 2002).
Prognostic Evaluation of Thyroid 
Cancer: What May Indicate 
Biomarkers
Different scoring systems, based on multiple 
regression analysis of combined predictive fac-
tors, have been proposed for stratifying patients 
with thyroid cancer into low and high risk prog-
nostic groups. The most used scoring system for 
predicting survival is the TNM staging system in 
which T indicates the extension of primary 
tumour, N is for condition of regional lymph 
nodes, and M for presence of distant metastases. 
The most recent (2002) version of TNM has 
underlined the importance of the age of patients 
together with the histological type in the behaviour 245
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and prognosis of FTC and PTC (Greene et al. 
2002; Hermanek and Sobin, 2002; Lang et al. 
2007a; Lang et al. 2007b). Two important changes 
made in respect to the previous edition need to 
be addressed. First, all tumors  2.0 cm in size 
but limited to the thyroid gland are now classiﬁ  ed 
as T1, while only tumors  1.0 cm were previ-
ously classiﬁ  ed as T1. This might lead to under-
treatment of some patients, exposing them to a 
higher risk of recurrence because of a less aggres-
sive initial treatment (i.e. lobectomy, as performed 
in some centers for T1 tumors). Second, nodal 
involvement causes a shift towards a higher stage 
and less favourable prognosis also in tumors that, 
because of small size and patient age, usually have 
favourable outcome. Available evidence, how-
ever, indicates that lymphnode metastases have a 
limited prognostic impact on overall survival 
(Hughes et al. 1996).
Other scoring systems include AMES, AGES 
and MACIS, the Ohio State University Scoring 
System. The AMES system is based in the combi-
nation of Age, distant Metastases, Extend and Size 
of the primary tumor. On this basis, patients with 
PTC and FTC are subdivided in a low-risk group 
(age  40 ys men, 50 ys women; no distant metas-
tases; older patients with intra-thyroid extension 
or minor capsular invasion and tumor size  5 cm) 
and a high-risk group (age  40 ys men, 50 ys 
women; distant mestastases; extra-capsular exten-
sion and size  5 cm of the primary tumor) (Cady, 
1998). The AGES system was developed at the 
Mayo Clinic in 1987 and included the following 
variables: Age, Grade (according to the Broder’s 
classiﬁ  cation), Extent (both local invasion and 
distant metastases) and Size of the primary tumor. 
In 1993, this scoring system was reviewed by the 
authors, excluding tumor grade and including 
distant Metatases, Age, Completeness of surgery, 
Invasion of the extra-thyroidal tissues and Size of 
the tumor (MACIS) (Hay et al. 1993). The Ohio 
State University Scoring System differ from the 
other systems because it not include age at diag-
nosis among variables. It distinguishes among 
patients with PTC and FTC, 4 categories according 
to tumor size, neck lymph-node metastases, multi-
focality, local invasion, and distant metastases 
(Mazzaferri and Kloos, 2001). The choice of the 
scoring system is mainly based on individual expe-
riences . No signiﬁ  cant difference was found in a 
comparative study of the TNM, AMES, AGES and 
MACIS systems. None of the many systems 
proposed has shown clear advantages in predicting 
thyroid cancer outcome (Brierley et al. 1997; Loh 
et al. 1997; Voutilainen et al. 2003; Lang et al. 
2007a ; Lang et al. 2007b). The TNM classiﬁ  ca-
tion, however, remains the most widely used 
because it provides a shorthand method to describe 
the extent of the disease and also because it uses 
parameters commonly used by oncologists for 
other organ tumors.
Prediction of thyroid cancer outcome is com-
monly based on circulating thyrogobulin measure-
ment in the complete absence of eutopic thyroid 
tissue. It is well established that thyroglobulin 
plays a reliable role in the monitoring of the well-
differentiated carcinoma course, after total thyroid-
ectomy. In fact, thyroglobulin assay allows 
detecting evidence of persistent or recurrent fol-
licular thyroid cancers (Pacini et al. 2006; Castagna 
et al. 2008).
The other commonly used serum marker of 
neoplastic diseases is the CT that sets the clinical 
stage of MTC recurrence following the total thy-
roidectomy (Hermanek et al. 2002; Loh et al. 1997; 
Jukkola et al. 2004; Akslen and LiVolsi, 2000; 
Schlumberger, 2004; Whitley and Ain, 2004; Kebebew 
et al. 2000). Moreover, immunohistochemical 
evaluation of CT expression in tumor specimens 
has also a prognostic value, because MTC tumors 
with a negative or scarce immunostaining for CT 
appear to be more aggressive.
New prognostic biomarkers are currently 
searched and tested. However, up to date it is 
unclear if any of these biomarkers might be more 
accurate than the currently used clinical staging 
systems.
Met over-expression in PTC has been correlated 
with early stages of disease and a better outcome. 
In fact, cases of poorly-differentiated PTC showed 
decreased expression of met. In a study from 
Belﬁ  ore and co-workers (Belﬁ  ore et al. 1997) it 
has been reported that negative/low met expression 
was predictive of distant metastases, and its clinical 
use was proposed to identify high risk patients.
BRAF mutations in PTC seems to correlate with 
a poor outcome of the disease (Namba et al. 2003; 
Nikiforova et al. 2003; Oler et al. 2005; Vasko et al. 
2005; Xing et al. 2005; Riesco-Eizaguirre et al. 
2006; Giannini et al. 2007; Kebebew E et al. 2007; 
Lupi et al. 2007; Rodolico et al. 2007), and a recent 
study (Frasca et al. 2008) suggests higher aggres-
siveness even in the microPTC. However, as noted 
above, a clear relationship between BRAF 246
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mutations and aggressive tumour behaviour has 
not been demonstrated in all studies (Puxeddu et al. 
2004; Kim et al. 2005; Trovisco et al. 2005; 
Fugazzola et al. 2006; Sapio et al. 2006; Abrosimov 
et al. 2007; Durante et al. 2007; Mitsiades et al. 
2007), and the predictive value of BRAF mutations 
remains uncertain.
The plasminogen activator (PA) system, which 
consists of two serine proteases, the urokinase PA 
(uPA) and the tissue-type PA (tPA), their two 
serpin inhibitors (PAI-1 and PAI-2), and the 
glycolipid-anchored receptor for the uPA (uPAR), 
is involved in cancer progression, since it enhances 
both distant metastasis and direct invasion. In 
particular, the uPA system has been implicated in 
neo-vascularization and in remodelling of the 
extracellular matrix, enhancing both cell prolif-
eration and migration and modulating cell adhe-
sion. Consistent with their role in cancer 
progression, high levels of expression of uPA, 
uPAR and PAI-1 correlate with poor patient prog-
nosis and outcome in several human cancers. For 
this reason, the uPA system components have been 
proposed as new prognostic markers for many 
cancer types, such as breast cancer (Dass et al. 
2007; Duffy, 2004; Duffy and Duggan, 2004). In 
the late few years, data regarding the expression 
of the uPA system in thyroid cancer has yielded 
valuable insights. It has been demonstrated that 
both human thyroid carcinoma-derived cell lines 
and most thyroid carcinomas (PTC, FTC and ATC) 
overexpress uPA, uPAR and PAI-1 (Ito et al. 1996; 
Packman et al. 1996; Zanetti et al. 1998; Smith 
et al. 1999; Kim et al. 2002; Chu et al. 2004; 
Ulisse et al. 2006). Furthermore, the highest levels 
of expression were found in anaplastic carcinomas 
(Horvatić Herceg et al. 2006), in well-differentiated 
carcinomas in which extra-thyroidal invasion or 
distant metastases had been present (Horvatić 
Herceg et al. 2006; Ulisse et al. 2006) and in PTC 
whose size exceeded 1 cm in diameter (Horvatić 
Herceg et al. 2006; Ulisse et al. 2006). Taken 
together, these data suggest that the PA system 
components have prognostic relevance in thyroid 
malignant tumors, as proven in other malignan-
cies, and may represent candidate molecular 
biomarkers of this type of cancer.
In MTC, a relationship between somatic RET 
mutations and bad prognosis has been described. 
Recently, Elisei et al. demonstrated that the pres-
ence of a somatic RET mutation correlates with 
a worse outcome of MTC patients, not only for 
the highest probability to have persistence of the 
disease, but also for a lower survival rate in a 
long-term follow-up. More interestingly, the 
presence of a somatic RET mutation correlates 
with the presence of lymph node metastases at 
diagnosis, which is a known bad prognostic fac-
tor for the deﬁ  nitive cure of MTC patients (Elisei 
et al. 2007).
The poor outcome and prognosis of MTC is also 
related to the highly chemoresistance of this malig-
nant neoplasia. Chemotherapy failure has been 
ascribed, at least in part, to the overexpression by 
MTC cells of the multidrug resistance proteins 
(MDRs), especially MDR1 and MDR2, transmem-
brane glycoproteins that antagonize intracellular 
accumulation of cytotoxic agents (Yang et al. 1991; 
Massart et al. 1995; Massart et al. 1996a; Massart 
et al. 1996b; Zatelli et al. 2005; Ruggeri et al. 
2006). The expression and function of MDR1 and 
MDR2 have been demonstrated to depend on 
cyclooxygenase (COX)-2 levels, which are found 
elevated in many human cancers (Taketo, 1998a; 
Taketo, 1998b; Williams et al. 1999; Patel et al. 
2002; Sorokin A, 2004) . In a recent study we 
evaluated the immunoexpression of MDR2 and 
COX2 in MTC samples and correlated the expres-
sions of these two proteins with pTNM and clini-
cal stages. We demonstrated that MDR2 is 
constitutively expressed in MTC cells, before any 
drug treatment, at higher pTNM stages (T4), while 
no expression is observed in lower pTNM stages 
(T2 and T3) (Ruggeri et al. 2006). This could 
explain the scarce response rate of MTC patients 
to chemotherapeutic strategies, based on doxoru-
bicin and cisplatin, in advanced and metastatic 
tumours. Therefore, the immunohistochemical 
expression of MDR2 may be useful in clinical 
practice before applying chemotherapic protocols 
enclosing doxorubicin and/or cisplatin. Further-
more, we observed a good correlation for the two 
proteins MDR2 and COX2 with both the patho-
logical and clinical staging criteria. A low MDR2 
expression, together with a high COX2 expression 
were associated with lower pTNM and clinical 
stages, and may also be considered as possible 
favourable prognostic markers, speciﬁ  c for early 
stages of MTC progression. On the contrary, in 
more advanced stages of MTC, we reported high 
MDR2 expression and low COX2 expression 
(Fig. 1D). So, the evaluation of MDR2 and COX2 
expression in MTC specimens may improve diag-
nostic and prognostic evaluation, and contribute 247
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to a better characterization and treatment of this 
type of tumour (Ruggeri et al. 2006).
Therapy of Thyroid Cancer: How 
a Biomarker May Become 
a Therapeutic Target
Because therapeutic options for patients with thy-
roid cancers that are aggressive and/or do not 
respond to standard therapies are limited, develop-
ing new therapeutic strategies is an important 
objective of research.
The RET and BRAF kinases and their down-
stream effectors represent possible targets for novel 
anticancer therapies.
The RET kinase represents a suitable target for 
novel drugs helpful in the treatment of both med-
ullary and papillary thyroid cancers, in which 
activating mutations in the RET proto-oncogene 
have been identiﬁ  ed. Several groups have searched 
for speciﬁ  c RET kinase inhibitors, able to inhibit 
autophosphorylation of the receptor, and have 
published preclinical studies with encouraging 
results (Carlomagno et al. 2002; Carlomagno et al. 
2003; Carlomagno et al. 2006; Petrangolini et al. 
2006; Vidal et al. 2005).
Likewise, activating point mutations of B-RAF 
occur early in the development of PTC, and seem 
to be related to a more aggressive behaviour in 
several studies. Clinical evaluation of B-RAF-
targeting drugs is undergoing and trials in thyroid 
cancer are planned. (Fagin, 2004; Ouyang et al. 
2006; Salvatore et al. 2006; Mitsiades et al. 2007).
Experimental evidence obtained using inhibi-
tors of uPA and uPAR has validated this system as 
a therapeutic target for the development of anti-
angiogenic and anti-metastatic therapeutic agents. 
In fact, it has been demonstrated that either inhibi-
tion of uPA catalytic activity or prevention of uPA 
binding to its receptor reduces tumor growth, ang-
iogenesis and metastasis (Mazaar et al. 1999; 
Duffy, 2004). Thus, uPA and its receptor might 
represent therapeutic biomarkers also for malignant 
thyroid neoplasms.
Finally, agents that may induce radioiodine 
uptake, such as histone deacetylase inhibitors and 
retinoids, represent another field in new drug 
development in thyroid cancer (Elisei et al. 2005; 
Cras et al. 2007).
Potential MTC therapeutic biomarkers are asso-
ciated with the expression of the MDRs in the 
tumor cells, as above reported (Ruggeri et al. 
2006). Several experimental studies suggest that 
resistance to chemotherapy of MTC may be cir-
cumvented by modulating the expression of MDR1 
and/or MDR2, focusing the attention of research-
ers on MDRs as novel therapeutic targets (Massart 
et al. 1996; Ratnasinghe et al. 2001; Fagin, 2004; 
Sorokin, 2004; Zatelli et al. 2005; Pérez-Tomás, 
2006; Ruggeri et al. 2006).
Conclusion
In this review we have evaluated the present 
knowledge about thyroid tumour markers with a 
special point of reference to the emergence of new 
markers arising from the demonstration of several 
pathways for the development of thyroid 
malignancy. The analysis of the literature indicates 
that only few of such thyroid markers may be 
presently employed in routine clinical practice, 
while the utility of most of them remain to be 
ascertained. Certainly, there is a strong need for 
new cytological and histological markers which 
could distinguish benign follicular adenomas from 
FTC. Furthermore, other areas require a careful 
investigation to look for markers of thyroid cancer 
recurrence that would serve as early detection 
systems. However, in the feverish context of the 
impelling demands to ﬁ  nd new decisive markers, 
it is advisable to be cautious in identifying each 
new molecule expressed from thyroid cancers as 
useful in clinical practice.
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